15 Non-Small Cell Lung Cancer Clinical Trials in Atlanta, GA (2026)

Q: How do I join a clinical trial in Atlanta?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you.

Recruiting Non-Small Cell Lung Cancer Studies in Atlanta

NCT05236114Recruiting

GEMINI-NSCLC: NSCLC Biomarker Study

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition t...

Atlanta, GA1,200 participantsTempus AI

View Study Details

NCT05384626Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activ...

Atlanta, GAPHASE1840 participantsNuvalent Inc.

View Study Details

NCT05379985Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....

Atlanta, GAPHASE1754 participantsRevolution Medicines, Inc.

View Study Details

NCT06745908Recruiting

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

This is a randomized, open-label, phase 3 clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (experimental arm) versus docetaxel monotherapy (control arm). Enro...

Atlanta, GAPHASE3507 participantsImmunityBio, Inc.

View Study Details

NCT07100080Recruiting

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy...

Atlanta, GAPHASE2500 participantsBristol-Myers Squibb

View Study Details

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Atlanta, GAPHASE1430 participantsBayer

View Study Details

NCT07541170Recruiting

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected K...

Atlanta, GAPHASE3400 participantsHoffmann-La Roche

View Study Details

NCT07195695Recruiting

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions ...

Atlanta, GAPHASE3400 participantsBoehringer Ingelheim

View Study Details

NCT07098338Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several ...

Atlanta, GAPHASE2278 participantsAstraZeneca

View Study Details

NCT07288177Recruiting

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. Th...

Atlanta, GAPHASE2240 participantsGenmab

View Study Details

NCT06667908Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can i...

Atlanta, GAPHASE2130 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT07659782Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer...

Atlanta, GAPHASE2105 participantsVerastem, Inc.

View Study Details

NCT06495125Recruiting

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

This phase II trial tests how well defactinib and avutometinib in combination with nivolumab works in treating patients with LKB1-mutant non-small cell lung cancer that has not responded (refractory) ...

Atlanta, GAPHASE250 participantsEmory University

View Study Details

NCT07140016Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some ...

Atlanta, GAPHASE140 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT06731270Recruiting

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

This phase II trial tests how well diclofenac works in treating patients non-small cell lung cancer (NSCLC) that may have spread from where it first started (primary site) to other places in the body ...

Atlanta, GAPHASE220 participantsEmory University

View Study Details

About Non-Small Cell Lung Cancer Clinical Trials in Atlanta

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Treatment has been transformed by targeted therapies and immunotherapy based on specific genetic markers.

There are currently 15 non-small cell lung cancer clinical trials recruiting participants in Atlanta, GA. These studies are seeking a combined 5,894 participants. Research is being sponsored by Tempus AI, Nuvalent Inc., Revolution Medicines, Inc. and 11 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Non-Small Cell Lung Cancer Clinical Trials in Atlanta — FAQ

Are there non-small cell lung cancer clinical trials in Atlanta?

Yes, there are 15 non-small cell lung cancer clinical trials currently recruiting in Atlanta, GA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Atlanta?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.

Are clinical trials in Atlanta free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.

What non-small cell lung cancer treatments are being tested?

The 15 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for non-small cell lung cancer.

Data updated October 17, 2026 from ClinicalTrials.gov